Skip to contentM
Marker Therapeutics, Inc.
M
MRKRMarker Therapeutics, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$759.14K$759.14Kderivedno prior Q4 2021 on file Net Income-$3.86M-$3.86MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$1,098,737N/M Operating Cash Flowderived-$6,305,422N/M Margins · derivedOperating margin144.7%
Net margin-508.0%
ended Dec 31, 2022 · filed Mar 22, 2023 · 81 d after period end